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TAAT, toxin-activating acyltransferase. 
ACP, acyl carrier protein. 
SAD, single-wavelength anomalous dispersion. 
SAXS, small angle x-ray scattering. 
SDS-PAGE, sodium dodecyl sulfate – polyacrylamide gel electrophoresis. 
GNAT, Gcn5-like N-acetyl transferase. 
NEM, N-ethylmaleimide.
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ABSTRACT  
Secreted pore-forming toxins of pathogenic Gram-negative bacteria such as Escherichia coli 
hemolysin (HlyA) insert into host cell membranes to subvert signal transduction and induce 
apoptosis and cell lysis. Unusually, these toxins are synthesized in an inactive form that requires 
post-translational activation in the bacterial cytosol. We have previously shown that the activation 
mechanism is an acylation event directed by a specialised acyl-transferase that uses acyl carrier 
protein (ACP) to covalently link fatty acids, via an amide bond, to specific internal lysine residues of 
the protoxin. We now reveal the 2.15Å resolution X-ray structure of the 172 amino acid ApxC, a 
toxin-activating acyl-transferase (TAAT) from pathogenic Actinobacillus pleuropneumoniae. This 
shows that bacterial TAATs are a structurally homologous family which, despite indiscernible 
sequence similarity, form a distinct branch of the GNAT superfamily of enzymes that typically use 
acyl-CoA to modify diverse bacterial, archaeal and eukaryotic substrates. A combination of 
structural analysis, small angle X-ray scattering, mutagenesis and cross-linking defined the 
solution state of TAATs, with inter-monomer interactions mediated by an N-terminal α-helix. 
Superposition of ApxC with substrate-bound GNATs, and assay of toxin activation and binding of 
acyl-ACP and protoxin peptide substrates by mutated ApxC variants indicates the enzyme active 
site to be a deep surface groove. 
 
SIGNIFICANCE   
Secreted pore-forming toxins of pathogenic bacteria such as E.coli and Bordetella pertussis insert 
into cell membranes to subvert signaling and cause cell death, facilitating infection of human and 
animal hosts. These toxins require a unique activation step before secretion, the covalent linkage 
of lipid groups to specific lysines of the inactive protoxin, directed by a specialised toxin-activating 
acyl transferase (TAAT). Here, we present the TAAT crystal structure, the soluble dimeric topology 
and likely active site, revealing that despite no discernible sequence similarity TAATs are a 
structurally and functionally distinct group of the GNAT superfamily of modifying enzymes. Our 
findings open the way to further understanding of the unique toxin activation, and the possibility of 
inhibiting toxin action. 
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INTRODUCTION 
Pathogenic bacteria secrete pore-forming protein toxins (PFTs) that target tissue and immune cell 
membranes to aid colonization and survival during infections, subvert cell signaling, induce 
apoptosis and promote cell lysis (1–8). Among Gram negative bacteria, large PFTs are secreted by 
pathogenic species of Pasteurella, Actinobacillus, Proteus, Morganella, Moraxella and Bordetella, 
exemplified by the 110kDa hemolysin (HlyA) of uropathogenic and enterohemorrhagic E.coli. 
These toxins play important roles in cystitis and pyelonephritis, hemorrhagic intestinal disease, 
periodontitis, pneumonia, septicemia, whooping cough and wound infections (4), and unusually 
they are made as an inactive protoxin, requiring post-translational activation before export (9–12).  
 Reconstituting the toxin activation reaction in vitro some time ago demonstrated that the 
essential modification is a novel fatty acid acylation, effected by a specialised coexpressed toxin-
activating acyltransferase, in E.coli HlyC, that uses acyl-acyl carrier protein (acyl-ACP) as the fatty 
acid donor (4, 13, 14). The acyltransferase  does not share significant sequence identity with other 
bacterial and eukaryotic enzymes and cellular acyltransferases from either the host or pathogen 
cannot substitute for HlyC in toxin activation. HlyC independently binds two separate 50-80 amino 
acid transferase recognition domains (15) each encompassing one of the internal target lysines 
K564 and K690 of E.coli protoxin HlyA, which are acylated by amide linkage, heterogeneously with 
fatty acids containing 14, 15 and 17 carbon chains (16, 17). Loss of the HlyC binding domain or 
substitution of protoxin K564 and K690, prevents fatty acyl modification and abrogates all toxin 
activity (14) as does loss of the transferase (18).  
Acylation is essential to the entire family of pore-forming toxins, B.pertussis proCyaA lysine 
acylation has also been demonstrated (19), and the toxin-activating acyltransferases (which we 
now call TAATs) have high sequence similarity and cross-activate other protoxins (4, 20–22). The 
TAAT activation mechanism is seemingly unique, and extensive site-directed mutagenesis has so 
far only identified a single potentially catalytic residue, His23 of HlyC (23–25). Structural 
information is essential to understand the toxin activation mechanism, and assess TAATs as a 
potential target for developing anti-virulence compounds that do not affect the host commensal 
flora. Here we determine the TAAT crystal structure, solution state, and likely active site.  
 
RESULTS 
The ApxC structure reveals TAATs as a distinct, closely conserved branch of the GNAT 
superfamily. 
Multiple TAAT genes were cloned and expressed in E.coli and where possible TAAT proteins were 
purified and screened for their amenability to crystallisation. This yielded the crystal structure of the 
172 amino acid Actinobacillus pleuropneumoniae ApxIC (hereafter ApxC) at 2.15Å resolution using 
the selenomethionine SAD method of phase determination. Crystallographic data and refinement 
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statistics are given in Table S1 and the structure is shown in Figure 1. Crystals belong to space 
group P212121 with 4 molecules per asymmetric unit (Fig. 1a). The four monomers are very similar 
and can be superposed pairwise with a mean rmsd of 1.7Å (Cα positions, residues 4-170).  
Structural diversity is largely limited to the last 7 residues of the C-terminus (mean rmsd for 
residues 5-165 is 0.84Å), and is not expected to be of physiological relevance as this region is not 
well-conserved among TAATs.  Each ApxC monomer is composed of a central five-membered 
β-sheet that is decorated by six α-helices (Fig. 1b). A distinctive split in the sheet is located 
between strands β3 and β4 which are the only strands that run parallel with one another. This split 
β-sheet is a key feature of the underlying fold, establishing a deep groove in the enzyme surface.  
 The overall fold of ApxC is clearly related to the Gcn5-like N-Acetyl Transferase (GNAT) 
superfamily, confirmed using structural-similarity searches with Dali (26). GNAT superfamily 
members mediate a diverse range of prokaryotic and eukaryotic processes ranging over antibiotic 
detoxification, circadian rhythm regulation and polyketide biosynthesis (27, 28). The closest 
structural match is the GNAT-like domain of CurA (rmsd 2.8Å, Dali Z score=8.6) (29), but robust 
structural similarity is also evident with other GNATs including the histone acetyl transferases 
(HATs), Gcn5 (rmsd 3.2Å, Z=7.8) (35),  p300/CBP (rmsd 3.1Å, Z=7.9) (30), Myst (rmsd 4.0Å, Z=3.1) 
(31), and acyl-amino acid synthase FeeM (rmsd 3.6Å, Z=6.6) (32). The ApxC structure is 
nonetheless distinguished from all other GNATs by the absence of a helical element that typically 
interacts with the planar nucleotide portion of CoA - this would be located between ApxC residues 
122 and 129 (Fig. 1b, teal), and the CoA diphosphate binding motif (“motif A” in GNATs (27)), that 
would otherwise be located between strand β3 and helix α3 (residues 97-99, Fig. 1b, orange). 
ApxC appears to be the only GNAT that lacks both of these two features, indeed the helix that is 
missing in ApxC is so uniformly conserved among GNATs that, alongside the split β-sheet, it is 
considered a defining feature of the GNAT fold (27, 28). In addition to the absence of CoA-
interacting elements, the long (25 residue) α-helix at the extreme C-terminus of ApxC (Fig. 1b, 
violet) is absent from all known GNAT structures, and a short helix and loop (residues 74 – 86, 
Fig. 1b, green) is present only in CurA (29). The close structural relationship between ApxC and 
members of the GNAT superfamily is remarkable given that there is no primary sequence similarity 
between these proteins. Even structure-driven sequence alignments produced with Dali reveal just 
6.4% sequence identity between ApxC and its closest structural match, the CurA GNAT domain, 
barely above that expected by chance (5%). 
In contrast to the low sequence identity between TAATs and other GNATs, the TAAT family 
itself is well conserved, illustrated by the multiple sequence alignment in Figure 2. ApxC shares 70% 
primary sequence identity with the best studied TAAT, E.coli HlyC, and can directly substitute for 
HlyC in activation of the E.coli hemolysin toxin in vivo (Figure S1), suggesting the ApxC structure 
is representative of the TAAT family and allowing us to construct high confidence homology 
models of homologues E.coli HlyC and Bordetella pertussis CyaC (coordinates available in SI). 
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TAATs adopt a dimeric arrangement in solution, mediated by an N-terminal helical interface. 
Gel filtration experiments using recombinant ApxC indicate an apparent molecular weight (42kDa) 
that is twice that expected for the monomer (21kDa) (Figure S2). Examination of the crystal 
packing in the ApxC structure shows four arrangements that could conceivably represent this 
dimer (Dimers I to IV in Figure 3a). Dimer I, underpinned by the unique C-terminal helix and Dimer 
III which appears twice in the asymmetric unit (Figure S3) were attractive possibilities but it was 
not obvious by inspection which interface reflects the physiological dimer and which are crystal 
contacts.  
We assessed the extent and quality of each of the four dimer interfaces by measuring the 
buried surface area and calculating the predicted stability using PISA (33) (Fig. 3a). Dimer IV had 
the lowest buried surface area and was predicted to be unstable but Dimers I, III and IV had 
substantial buried surface area and were all predicted to be stable. Analysis of scattering data from 
small angle X-ray scattering (SAXS) (Fig. 3b) indicated that the particle has an estimated 
molecular weight of ~38.8kDa, a 28Å radius of gyration and a probable maximum dimension of 
~77Å. Ab initio shape reconstructions of the solution particle were consistent with a 2-fold 
symmetric bilobal globular dimer (Fig. 3b). Comparison of the scattering data with theoretical 
profiles predicted for each dimer was used to assess which arrangement most closely resembles 
the solution particle (Fig. 3c). Both Dimer I and Dimer III have low χ2 values indicating a good fit 
between prediction and experiment while Dimers II and IV do not. Inspection of the predicted P(r) 
profiles (Fig. 3c, black lines) shows that both Dimers I and III are close to the experimentally-
derived profile (blue lines) consistent with bilobal structures with a maximum dimension of ~80 Å, 
while Dimers II and especially IV deviate significantly suggesting that the maximum dimensions of 
these dimers are respectively 10Å and 15Å too short to be consistent with the data. Taken together, 
the surface areas, predicted stabilities and SAXS data excluded Dimers II and IV but did not 
satisfactorily discern between Dimers I and III. 
 We therefore applied two further molecular genetic experimental approaches.  Firstly, we 
conducted in vitro cross-linking experiments with the aim of covalently trapping the physiological 
dimer using experimentally-engineered cysteine residues placed independently at each potential 
dimerization interface.  Secondly, we used a bacterial 2-hybrid system (34) to monitor the 
inter-monomer interaction in vivo after introducing disruptive mutations to each putative interface. 
The interface structures, genetic interventions and results are presented in Figure 4. Both Dimers I 
and III are 2-fold rotationally symmetric, so it was possible to introduce single cysteines close to 
the relevant rotation axis to generate potential cross-link sites, namely Gly12Cys within the N-
terminal helix to specifically trap Dimer III, and Lys160Cys within the C-terminal helix to trap 
Dimer I (Fig. 4a). Cross-linking of the dimer was successful with Gly12Cys, but not Lys160Cys, 
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and no cross-linked dimer was generated by the wild type protein, nor when solvent accessible 
cysteines were pre-blocked with NEM (Fig. 4b). In parallel, we used a bacterial 2-hybrid assay (34) 
in which wildtype ApxC dimerization results in reporter activity (β-galactosidase activity, blue spot, 
top box Fig. 4d). Mutations were engineered to disrupt either the N-terminal helix within the Dimer 
III interface (Gly12Ala, Gly12Glu, Ala15Glu, and Ala19Glu substitutions, Fig. 4c) or the intertwined 
C-termini of Dimer I by a 10 amino acid deletion (Fig. 4e), all variant fusion proteins expressed 
comparably (Figure S4). The Gly12Glu and Ala15Glu mutation disrupted the dimer (white spots, 
Fig. 4d), while deletion of the C-terminus had no effect (Fig. 4f). Taken together these experiments 
unambiguously define Dimer III as the state of the enzyme in solution.  
 
Identification of the TAAT active site within a deep surface groove. 
The structural similarity between TAATs and the GNATs provoked a search for shared catalytic 
residues in structural superimpositions of ApxC with key members of the Gcn5 (35), Hat1 (30), 
Myst (36), p300/CBP (30), FeeM(32) and CurA (29) GNAT subfamilies. Statistics for the structural 
superpositions are given in Table S2 alongside summaries of the expected active site residues 
and the ApxC residues to which they most closely align. Our search confirmed that TAATs do not 
contain catalytic residues established for other GNATs including the buried glutamates found in the 
Gcn5 and Hat1 families (27, 28), the cysteine and glutamate found in Myst (36), or the 
phenylalanine and tyrosine residues thought responsible for substrate alignment in the CBP/p300 
subfamily (30). To assess potential substrate-binding sites, ApxC was also compared with 
substrate-bound structures of the GNATs Gcn5 (35) and FeeM (32) (Figure 5). Gcn5, the 
archetypal member of GNAT superfamily is a histone acetyltransferase that catalyses the acetyl 
CoA dependent acylation of a sequence-internal histone lysine residue. The crystal structure of the 
ternary complex (35) formed between Gcn5, CoA and a peptide representing the histone tail 
superposes well with ApxC with parts of both substrates overlaying portions of the TAAT active site 
groove (Fig. 5a). FeeM catalyses the acylation of tyrosine using FeeL, an ACP-like protein, as acyl 
donor. Structural superposition of FeeM with ApxC places the acyl chain of the N-lauroyl tyrosine 
product (co-crystallised with FeeM) within a hydrophobic portion of the TAAT surface groove (Fig. 
5b). These superpositions suggest that the deep groove observed for ApxC is the likely substrate 
binding site. 
To confirm the location of the active site and to identify key residues, we generated alanine 
mutants of residues lining the groove, in particular targeting polar residues conserved in the TAAT 
family (Fig. 2). These included His24 for which the equivalent residue in E.coli TAAT HlyC has 
been shown to be important (24), Ser21 and Asp93 which together with His24 have a three 
dimensional arrangement reminiscent of catalytic triads found in non-GNAT acyltransferases and 
proteases). The structural context of these targeted residues is shown in Fig. 6a, and relative 
TAAT activities of ApxC alanine-variants assessed by erythrocyte lysis of variant-activated toxin 
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are indicated in Fig. 6b. The Ser21Ala substitution caused only a marginal (21%) reduction in 
TAAT activity, inconsistent with a role as a nucleophile within a catalytic triad. A role for the TAAT 
family conserved cysteine residue can similarly be excluded as the ApxC structure reveals Cys58 
is completely buried within the core of the protein where it is inaccessible to substrates (Fig S5a, 
b). In agreement with this, the Cys58Ala variant has wild type levels of activity (Fig. S5c). In 
contrast, both Asp93 and Arg121 alanine variants were profoundly affected by mutation with TAAT 
activities less than 1% of the wild type. The His24 and Asn35 variants were also significantly 
impaired, although not to the same degree, with measurable activities of c.5% of wild type. 
To probe the roles of these four important residues, we performed bacterial 2-hybrid 
experiments to assess their ability to engage with TAAT substrates (i.e. the protoxin and ACP). All 
four alanine-substituted variants were able to dimerise efficiently indicating that each is properly 
folded (Fig. 6c, left), and all engaged with a 58 amino acid peptide (residues 679-736 of the 
protoxin) known to be the recognition sequence for TAAT spanning K690 (15) (Fig. 6c, centre). 
Asn35, Asp93 and His24 alanine variants were also able to bind ACP, but the Arg121Ala mutant 
was not (Fig. 6c, right) despite being expressed at comparable level to the wild type (Fig. 6b). We 
therefore anticipate Arg121 mediates interaction with ACP while the remaining essential residues, 
His24, Asn35, and Asp93, are likely to have roles in catalysis. The putative active sites 
encompassing these residues in the surface groove are on opposing faces within the dimer, not in 
close juxtaposition (Fig. 6d). 
 
DISCUSSION 
We have described the high resolution crystal structure (Fig. 1), solution structure (Fig. 3b), 
dimerisation interface (Figs. 3 & 4) and active site location (Fig. 6) of ApxC, revealing the close-
knit family of toxin-activating acyltransferases (TAATs) as a new subdivision of the GNAT 
superfamily. While TAATs retain the characteristic GNAT split in the central β-sheet that underlies 
the putative substrate-binding groove, they lack the structural motifs typically associated with CoA 
binding, including both the nucleotide-interacting helix and diphosphate-binding motif that are 
considered core elements of the characteristic GNAT fold. A long C-terminal α-helix and small 
loop-helix feature further distinguish TAATs from other GNATs (Fig. 1). 
 In vitro SAXS (Fig. 3) and in vivo two-hybrid analyses (Fig. 4) confirmed indications from 
gel filtration (previously with HlyC (18) and here with ApxC) that TAATs are dimers in solution. 
Analysis of biophysically tenable dimers abstracted from the crystal structure using a combination 
of experimental solution scattering data, targeted mutagenic disruption and cross-link locking of 
potential inter-monomer contacts, firmly established the dimer topology (Fig. 3a, Dimer III). The 
dimer interface is largely hydrophobic, with the close approach of the N-terminal helices facilitated 
by the small side chains of Gly12 and Ala15. Consequently, the proposed active sites of the 
monomers, each located within a surface groove, are topologically distinct within the context of the 
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dimer and unlikely to act in concert (Fig. 6d). 
 The lack of typical GNAT CoA-binding features in TAATs is understandable from a 
functional perspective as TAATs use ACP as the substrate acyl donor and not CoA. However, 
FeeM is also dependent on an ACP-like acyl donor (FeeL) yet retains the GNAT-typical CoA-
interacting helix. The interaction between FeeM and FeeL has been partially mapped by mutation 
and involves the helical region that is absent in TAATs (32) suggesting the TAAT:ACP interaction 
must be distinct from that of FeeM:FeeL. The only other structurally characterised GNAT known to 
interact with ACP is CurA, a large multidomain protein involved in polyketide synthesis. The CurA 
GNAT domain interacts with both CoA and an ACP-like internal domain facilitating acyl transfer 
between these substrates (29). CoA binding in CurA occurs in typical GNAT fashion while a distinct 
ACP binding site has been proposed to lie in a separate tunnel that connects directly to the CoA 
binding site. A similar binding mode is possible in TAATs as the proposed ACP-binding tunnel of 
CurA partially overlaps the ApxC surface groove. 
 Structure-led mutagenesis of the TAAT surface groove, the putative active site, revealed 
two residues, Asp93 and Arg121, as essential to function and Asn35 and His24 as important. 
Mutation to alanine did not impair dimerisation, and while all four alanine variants still interacted 
with the target protoxin, mutation of Arg121 uniquely abrogated binding of ACP. In other unrelated 
ACP-binding enzymes positively charged residues mediate direct interactions with phosphates of 
the ACP phosphopantetheine group (37) or the negatively charged residues of ACP (38), and so it 
seems likely that Arg121 plays a similar role in the TAAT:ACP interaction. For Asn35, the 
chemistry of the asparagine side chain precludes a role in acid-base catalysis and amide group is 
unlikely to be a nucleophilic, but it may have a role in orientating substrates or other essential 
residues e.g. Asp93 to which it is hydrogen bonded.  
 His24 and Asp93 are both candidates to be true catalytic residues and plausible roles within 
the context of the two most likely acyl transfer schemes are outlined in Figure S6. In the first 
scheme, a ternary complex is formed between the enzyme and both substrates facilitating direct 
nucleophilic attack of the protoxin target lysine on the acyl-ACP thioester with subsequent 
expulsion of ACP (a “direct attack” mechanism, Fig. S6a). In the second, the reaction proceeds in 
two steps through formation of a covalent acyl-enzyme intermediate that is resolved by attack of 
the toxin receptor lysine (“covalent catalysis”, Fig. S6b). In either mechanistic scheme, analogy to 
other GNATs, particularly histone acetyltransferases such as Gcn5 and Hat1, suggests Asp93 acts 
as general base to deprotonate the receptor lysine of the protoxin, and in the specific case of 
covalent catalysis it could additionally deprotonate the catalytic nucleophile. His24 would then 
serve as general acid protonating the ACP thiolate leaving group in the direct attack scheme, or 
else as the enzymatic nucleophile in the covalent catalysis scheme. 
 That TAATs represent a novel subfamily of GNATs is an important finding as kinetically 
characterised GNATs appear to use a ternary complex to facilitate transfer of acyl groups from one 
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substrate to the other giving strong support for a ternary complex (direct attack) based mechanism 
(27, 35, 39, 40). This agrees with early kinetic experiments on HlyC (41), but is at variance with 
other results favouring sequential binary interactions between enzyme and substrate (42), and 
observations of acylenzyme formation inferred from experiments with radiolabelled fatty acids (23, 
24). Incubation of TAAT HlyC with acyl-ACP does yield acylated enzyme and is dependent on 
integrity of the active site histidine (equivalent to ApxC His24) (23). However, direct histidine 
modification has not been demonstrated and in other GNATs internal enzyme acylation is 
suggested to be a self-regulatory feature (36, 43), so it is not clear whether the acylated TAAT is 
an acyl transfer intermediate, regulatory state, or artefact of acyl donor interaction in the absence 
of the acyl acceptor. 
In support of ternary complex formation, the TAAT surface groove is of comparable size to 
that of Gcn5 and so probably big enough to accommodate both the acylated phosphopantetheine 
arm of acyl-ACP and the protoxin lysine, if not also a substantial part of unfolded protoxin. Based 
on the superposition of TAATs with other GNATs (Fig. 5) and our identification of the TAAT 
catalytic residues (Fig. 6) we illustrate how TAATs could bring together the acyl- ACP and toxin 
substrates to effect toxin activation in Fig. 7. The central location of the active site residues within 
the groove (yellow, Fig. 7b) hints that each substrate could be bound on opposing faces of the 
enzyme with acyl transfer chemistry occurring at the crux of the split β-sheet. In support of this, the 
ACP-interacting arginine (Arg121 in ApxC) is located on the same face of the enzyme as the 
portion of the active site groove that accommodates a lauryl acyl chain in FeeM (Fig. 7a) 
suggesting the likely ACP binding site (Fig. 7b, green) and this is the opposite face to which the 
histone tail locates in the Gcn5 ternary complex (Fig. 7a, blue) suggesting a possible protoxin 
binding site, (Fig. 7b, blue). If TAATs do use a ternary complex it seems likely they would also use 
the direct attack mechanism typical of other GNATs. Otherwise, TAATs will be of significant 
interest as a truly unique subset of the GNAT superfamily. 
 Elucidation of the TAAT protein structure, solution oligomer and active site represents a 
significant step forwards towards understanding how bacterial pore-forming toxins are activated. 
The structural and possibly functional distinction between TAATs and all known GNAT families 
also identifies these enzymes as possible targets for developing new anti-virulence compounds. 
 
METHODS 
Cloning and site-directed mutagenesis. 
The apxIC gene was PCR-amplified from Actinobacillus pleuropneumoniae (ATCC27088) genomic 
DNA using primers ApxC QE80 F and ApxC QE80 R (all primer sequences are given in Table S3) 
engineered to encode restriction sites in the 5'-ends. The PCR product was digested with BamHI 
and HindIII and ligated into pQE80 (Qiagen). Site-specific mutations were introduced using 
QuikChange (Stratagene). Clones from PCR-amplified DNA were sequenced (Source Bioscience). 
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TAAT genes from uropathogenic E.coli, enterohemorrhagic E.coli, Bordetella pertussis, 
Mannheimia hemolytica, Aggregatibacter actinomycetemcomitans, and Aeromonas hydrophila 
were cloned with a similar strategy. For bacterial 2-hybrid ApxC or variant was amplified with 
primers ApxC HindIII F/ApxC SacI REV (ApxC HindIII F/ApxC 161 R for the ∆162-172 construct), 
digested with HindIII and SacI and cloned into pUT18 and pKNT25 resulting in the adenylate 
cyclase fragment being placed at the C-terminus of ApxC. Similarly E.coli ACP and a fragment 
corresponding to HlyA residues 679-736 were amplified with primer pairs ACP F/ACP R and  HlyA 
679 F/HlyA 736 R respectively, digested with HindIII-SacI and cloned into pUT18 digested with the 
same enzymes. 
 
ApxC protein expression and purification. 
N-terminally His-tagged ApxC was produced in E. coli C41 cells (44) bearing plasmid pQE80/ApxC, 
grown in 2TY medium at 30 °C until A600 0.6 then the temperature was reduced to 18
 °C and 
expression induced with 0.1mM IPTG for 16h. Cells were harvested by centrifugation (10,000 g) 
and resuspended in 50mM HEPES pH 7.5, 400mM NaCl, 5% (v/v) glycerol supplemented with 
Complete EDTA-free protease inhibitor mixture (Roche) and broken by two passages through a 
cell disruptor (30,000 psi). Unbroken cells were removed by ultracentrifugation at 150,000 g for 1h 
at 4°C. The supernatant was supplemented with 4mM Imidazole and added to Profinity IMAC resin 
(Biorad) for 1h at 4°C. Protein-bound resin was washed with 25mM HEPES pH 7.5, 500mM NaCl, 
8mM Imidazole, 0.1% Triton X-100, then with the same buffer without Triton X-100, and eluted with 
25mM HEPES pH 7.5, 200mM NaCl, 250mM Imidazole. Protein fractions were pooled, 
concentrated and loaded onto a Superdex S75 column equilibrated in 25mM HEPES pH 7.5, 
200mM NaCl. Peak fractions were concentrated to 5mg/ml in an Amicon 10kDa centrifugal filter 
device (Millipore). For phase determination, SeMet-labelled ApxC was produced in E.coli B834 
transformed with pQE80/ApxC. Cells grown in M9 minimal medium supplemented with 50 mg/ml 
methionine to A600 0.8, were resuspended in minimal media lacking methionine for 20min and 
selenomethionine added to 50mg/ml final concentration. After another 20min, expression was 
induced by IPTG as before, and SeMet-labelled protein purified as unlabelled protein except that 
1mM TCEP (Merck) was added to buffers. Protein identity and SeMet incorporation were verified 
by mass spectrometry (PNAC, Cambridge Department of Biochemistry). 
 
Crystallisation and structure determination. 
ApxC crystals were obtained via the sitting-drop vapour diffusion method using crystallisation 
reagent composed of 32% (w/v) PEG 300, 100mM Phosphate/Citrate Buffer pH 4.4, and a protein 
solution of 5mg/ml ApxC in 150mM NaCl, 20mM HEPES pH 7.5. Sitting drops were formed by 
mixing 2μL protein solution with 1μL crystallization reagent and equilibration over a 500μL volume 
of the crystallization reagent at 15°C in 24-well plates. Crystals appeared after 3 days and were 
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harvested a few days later. For freezing, crystals were transferred into a cryoprotectant solution 
composed of 20mM Phosphate/Citrate buffer, 50mM NaCl, 7.5% (w/v) PEG 300 and 10% (v/v) 
glycerol, then to the same solution containing 20 % (v/v) glycerol before harvesting with a cryoloop 
and flash-freezing in liquid nitrogen. Crystals of the selenomethionine derivative were prepared 
similarly, although were typically much smaller than those of the native protein. X-ray diffraction 
data were collected on beamlines I02 and I04 of Diamond Light Source, UK. Structure 
determination utilised the Se-SAD method of phase determination aided by programs from both the 
PHENIX (45) and CCP4 software suites (46). X-ray data were indexed and integrated using 
MOSFLM (47) and scaled using SCALA. A partial substructure of Selenium sites was identified 
using HYSS (48) and experimental phases calculated with PHASER (49). Density modification 
using PARROT (50) benefitted from identification of a 2-fold non-crystallographic symmetry relating 
a subset of the heavy atom sites. Manual inspection of the density-modified maps identified further 
selenium sites and derivation of the likely 4-fold NCS operators relating each of the four monomers 
in the asymmetric unit. After further density modification using 4-fold NCS averaging, an initial 
selenoApxC model was built with BUCCANEER (51) and completed with iterative rounds of 
manual model-building with COOT (52) and refinement with REFMAC (53) using NCS restraints. 
Refinement was switched to an isomorphous, high-resolution, native dataset maintaining the same 
'free' reflection set, with NCS-restraints on the monomers relaxed and solvent components such as 
ordered water molecules and crystallization reagents added to complete the crystallographic 
model. Further model validation used PROCHECK (54), and RAMPAGE (55). The final model 
comprises 4 molecules of ApxC, 219 waters and a citrate molecule. Atomic coordinates and 
structure factors are deposited in the Protein Data Bank, accession code 4WHN.  
 
Structure analysis, sequence alignments and homology modelling. 
Buried surface areas were calculated using AREAIMOL (56) with a solvent probe radius of 1.2Å. 
Predicted dimer stability was assessed with PISA (33). Root mean square deviations (rmsds) were 
calculated over all Cα atoms after alignment using superpose in the CCP4 suite (57). Figures were 
prepared in Pymol (58). For homology modelling, a single monomer of ApxC was used as a 
template on which to impose the sequence of other TAATs using the Phyre2 server in sequence 
threading mode (59). For multiple sequence alignments, amino acid sequences were processed 
using Clustal Omega (60) and conserved residues mapped with ESPript (61). Further editing to 
add the secondary structure elements and essential residues was performed manually using the 
GNU Image Manipulation Programme (GIMP). 
 
Small angle X-ray scattering (SAXS) analysis. 
Small angle X-ray scattering was conducted at the PETRA P12 SAXS beamline in Hamburg, 
Germany (Deutsches Elektronen-Synchrotron – DESY) using purified ApxC protein in buffer 20mM 
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HEPES pH 7.5, 150mM NaCl. Data used in final analysis is the average of 4 separate samples 
(each the average of 10-20 frames) collected using 56μM ApxC. Computational analysis of the 
data used the ATSAS package of programs (62). Inspection and characterisation of the data used 
PRIMUS (63) and GNOM (64), while ab initio shape reconstruction used DAMMIN (65). The final 
particle was constructed by averaging 20 independent models with DAMAVER (66) before filtering 
with DAMFILT (66). The final model also used enforced P2 symmetry, but runs without symmetry 
restraints produced similar results. CRYSOL (67) was used to compare predicted scattering 
behaviour of dimers/monomers in our crystal structure with scattering data obtained in solution. 
 
Hemolysis assay of toxin activation. 
E. coli MC1061 (TolC positive) cells bearing plasmids expressing the export system HlyBD (LG575 
(68)) and HlyA (LG583 (68)) were transformed with pQE80 vector alone or expressing wildtype or 
mutant ApxC. Bacteria were grown overnight on blood agar plates supplemented with 20μg/mL 
chloramphenicol and 50μg/mL carbenicillin. LB cultures supplemented with antibiotics to maintain 
plasmid selection were grown to A600 0.8 and cells removed. Dilutions of supernatant containing 
secreted HlyA were added to 2% washed horse erythrocytes, 20mM CaCl2, 150mM NaCl and 
incubated 30min at 42°C. Hemolytic activity was assayed as hemoglobin release at A543 after 
subtracting the absorbance of the vector control. Assays were performed in triplicate, with each 
absorbance measurement itself the mean of triplicates.  
 
Bacterial two-hybrid assays. 
E.coli BTH101 was co-transformed with recombinant pUT18 and pKNT25 plasmids expressing the 
protein of interest fused to either the T18 or T25 domain of B.pertussis CyaA and grown at 30°C. 
Overnight culture (LB with 100 μg/mL carbenicillin and 50μg/mL kanamycin) grown at 30°C was 
spotted (2µl) on LB agar containing 0.5mM IPTG and 40µg/mL X-GAL. After overnight incubation 
at 30°C plates were photographed under white light. β-galactosidase assays were performed as 
described (69). 
 
Cross-linking. 
Cysteine variants of ApxC were purified as for the wildtype protein except that 2mM TCEP was 
added to all buffers. For cross-linking reactions, TCEP was removed by desalting column and 
100µM CuCl2 added to 50μg of protein in 25mM HEPES pH7.5, 150mM NaCl and incubated at 
25ºC for 30 minutes before addition of 10mM EDTA (to chelate copper) and 5mM NEM (to block 
free cysteines). Reactions were analysed by SDS PAGE. For the control reaction (pre-block) 
samples were pretreated with EDTA and NEM prior to addition of CuCl2. 
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Western blot analysis. 
Samples were resolved on SDS PAGE, transferred to nitrocellulose membrane and immunoblotted 
with anti-His (Qiagen) or anti-cyaA (Santa Cruz) antisera as appropriate. These were detected with 
a chemiluminescence kit (GE Healthcare ECL) or fluorescence imaging (Odyssey Licor) 
respectively.  
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FIGURE LEGENDS 
Figure 1: Crystal structure of the toxin-activating acyl transferase ApxC. (a) The asymmetric 
unit contains four monomers of ApxC. An imperfect 2-fold non-crystallographic symmetry axis 
(dotted red line) relates two pairs of monomers. (b) Structure of a single monomer indicating 
structural features that discern TAATs from other members of the GNAT superfamily. 
 
Figure 2: Multiple sequence alignment for key members of the TAAT family. Secondary 
structure of ApxC (consensus of the four monomers in the crystal structure) is shown immediately 
above the alignment of TAAT sequences ApxC (Actinobacillus pleuropneumoniae), HlyC 
(Uropathogenic Escherichia coli), AaLktC (Aggregatibacter actinomycetemcomitans), MhLktC 
(Mannheimia hemolytica) and CyaC (Bordetella pertussis). The α-helices indicated are shown as 
tubes (blue), β-strands by arrows (green). Conserved residues are highlighted red, and important 
active site residues identified later (His24, Asn35, Asp93 and Arg121) are shown in gold. Features 
that differentiate TAATs from other GNATs are highlighted using the same colour scheme as in 
Figure 1b. 
 
Figure 3: X-ray analysis of potential ApxC dimers in crystallo and in solution. (a) The four 
dimeric arrangements of ApxC extracted from the crystal structure (I-IV) indicating buried surface 
area and predicted free energy of dissociation (∆G, positive values indicate favourable association) 
obtained from PISA, (33). (b) Small Angle X-ray Scattering (SAXS) analysis of ApxC in solution. (i) 
The measured SAXS scattering intensity profile is shown in blue (56μM ApxC) and the predicted 
scattering profile of the solution model in black, while the solution structure of ApxC, a filtered 
model derived from the average of 20 models, is shown inset. (ii) Distance distribution analysis of 
each of the candidate ApxC dimers verses the SAXS data. The quality of the fit can be seen by 
comparing predicted P(r) profile in black with the measured profile in blue, quantified by the χ2 
value shown inset. 
 
Figure 4: Experimental determination of the ApxC solution dimer. (a) Locations of engineered 
cysteine residues (marked with spheres Gly12, blue; Lys160 orange) with respect to two dimeric 
arrangements, (Dimer III, left; Dimer I, right). (b) Cysteine cross-linking of purified wild type (WT) 
ApxC or cysteine variant. Protein (50µg) was treated with or without 100µM CuCl2 (X-linker) for 30 
minutes at 25ºC to catalyse cross-linking of proximal cysteines before blocking free cysteines with 
5mM N-ethylmaleimide (NEM). Pre-block reactions were treated with NEM and EDTA prior to 
addition of cross-linker. (c) Locations of Gly12, Ala15 and Ala19 within the N-terminal α-helix at the 
Dimer III interface. (d) Bacterial 2-hybrid assay of homodimerisation of WT ApxC or indicated 
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variants. Interaction was assessed qualitatively by blue colouration and quantitatively by 
β-galactosidase activity (right), expressed as a percentage of the wild type ± SD. (e) Location of an 
engineered C-terminal deletion (Δ162-172) in context of Dimer I. (f) Bacterial 2-hybrid assay 
assessing homodimerisation of ApxC (Δ162-172), details as for (d).  
 
Figure 5: Superposition of the TAAT ApxC with Gcn5 and FeeM. (a) Superposition of ApxC 
(white) with Gcn5 (wheat). The two Gcn5 substrates are CoA (red) and histone H3 peptide (blue). 
(b) Superposition of ApxC (white) with FeeM (pink). The FeeM N-lauroyltyrosine ligand is shown in 
green. 
 
Figure 6: Definition of the TAAT active site. (a) Location of the postulated substrate-binding 
groove and close-up of the active site (boxed). Side chains of key active site residues are shown in 
stick representation. (b) TAAT activity of active site variants assayed by in vivo toxin activation 
(erythrocyte lysis, percentage of wild type activity ± SD with immunoblot showing expression 
underneath. (c) Bacterial 2-hybrid experiments testing ApxC dimerization (left), interaction with 
TAAT-binding protoxin peptide (residues 679-736 - HlyA*, centre), and ACP binding (right) for wild 
type (WT) ApxC and mutant variants. Interaction was assessed qualitatively by blue colouration 
and numerically by β-galactosidase activity (right), expressed as a percentage of the wild type (top 
row) ± SD after subtraction of the negative control. (d) Solid surface representations of ApxC 
showing the location of the active site of each monomer in context of the soluble dimer (blue lasso), 
with important active site residues in yellow. 
 
Figure 7: A model for ternary complex TAAT function. (a) Location of the acyltyrosine ligand 
(green) from the FeeM:acyltyrosine co-structure and histone H3 peptide (blue) from the 
Gcn5:CoA:H3 peptide ternary complex after superposition with ApxC (white). (b) Proposed 
locations of the acylACP and protoxin binding sites on opposite faces of the TAAT enzyme (ACP-
binding site green; protoxin binding site blue). The substrates are predicted to meet at the crux of 
the split β-sheet where the catalytic residues (yellow) are located. Arg121 (essential for ACP 
binding) is annotated. 
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Supplemental table 1: Crystallographic data and refinement statistics 
 Se-Methionine Derivative High Resolution Native 
Data Collection   
Beam line DLS I24 DLS I04 
Wavelength (Å) 0.9700 0.9796 
   
Crystal Parameters   
Space Group P 21 21 21 P 21 21 21 
Unit Cell Dimensions (Å) 73.8, 88.8, 130.8 82.45, 86.37, 131.16 
Unit Cell Angles (°) 90, 90, 90 90, 90, 90 
Mosaic Spread (°) 0.87 0.37 
   
Reflection Data   
Resolution Range (Å) 88.78-2.65 (2.79-2.65) 54.29-2.15 (2.22-2.15) 
Unique Reflections 25,047 (3,129) 51,711 (4442) 
Rsym 0.189 (0.679) 0.104 (0.804) 
I/σ(I) 11.7 (2.9) 12.6 (2.5) 
Completeness (%) 97.6 (86.1) 100 (100) 
Anomalous Completeness (%) 97.2 (84.0) 100 (100) 
Multiplicity 10.8 (7.0) 7.2 (7.3) 
Anomalous Multiplicity 5.7 (3.6) 3.7 (3.7) 
Wilson B (Å
2
) 43.8 25.9 
   
Phase Calculations   
Phasing Method SAD Molecular replacement with SeMet 
model 
Figure of Merit 0.24 - 
Figure of Merit (after density 
modification) 
0.65 - 
   
Refinement 
†
   
Resolution (Å) - 54.29-2.15 
Number of Reflections - 49,014 
Rwork - 0.200 
Rfree - 0.242 
Rcryst - 0.202 
Rms(Bond Lengths) (Å) - 0.016 
Rms(Bond Angles) (°) - 1.729 
   
Model Composition   
Protein atoms - 5,636 
Waters - 219 
Other - 13 
   
Model B-factors   
Protein atoms (Å
2
) - 39.7 
Waters (Å
2
) - 36.0 
Other (Å
2
) - 65.1 
   
Ramachandran Statistics 
‡
   
Favoured (%) - 99.7 
Allowed (%) - 0.3 
Outliers (%) - 0 
   
 
† 
As reported by Refmac. 
‡ 
As reported by Rampage. 
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Supplemental table 2: Superposition statistics for matching ApxC to key GNATs. 
PDB 
code 
Protein RMSD Dali 
Z-Score 
Putative GNAT 
active site 
residues 
Spatial equivalents in 
TAAT, ApxC (4WHN) 
2REE CurA 2.8Å  8.6 - - 
1KUV Serotonin acyl 
transferase 
3.0Å  8.2 - - 
1BOB Hat1 4.0Å  2.9 Glu255, Asp256 Ala119, Ile120 
1CM0 P300/CBP 3.1Å  7.9 Glu570, Phe617, 
Tyr616 
Trp90, absent, absent 
1YGH Gcn5 (yeast) 3.1Å  7.3 Glu173 Trp90 
1QSN Gcn5 (Tetrahymena) 3.2Å  7.8 Glu122 Trp90 
2G0B FeeM 3.6Å  6.6 Glu94 Trp90 
1MJA Myst 4.0Å  3.1 Cys304, Glu337 Asp93, Ala119 
 
 
  
Greene et al  : Page 31 of 37 
 
Supplemental Table 3: Primers used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Restriction sites 
underlined 
  
Primer Sequence 5′→3′ 
ApxC QE80 F GCGCGGATCCAGTAAAAAAATTAATGGATTTGAGGTTTTAG 
ApxC QE80 R GCGCAAGCTTTTAGCTATTTACTAATGAAAATTTAAAATTTTG 
ApxC HindIII F GCGCAAGCTTGATGAGTAAAAAAATTAATGGATTTGAG 
ApxC SacI R GCGCGAGCTCCCGCTATTTACTAATGAAAATTTAAAATTTTG 
ApxC G12A F GGATTTGAGGTTTTAGCAGAGGTGGCATGGTTATG 
ApxC G12A R CATAACCATGCCACCTCTGCTAAAACCTCAAATCC 
ApxC G12E F GGATTTGAGGTTTTAGAAGAGGTGGCATGGTTATG 
ApxC G12E R CATAACCATGCCACCTCTTCTAAAACCTCAAATCC 
ApxC A15E F GGTTTTAGGAGAGGTGGAATGGTTATGGGCAAG 
ApxC A15E R CTTGCCCATAACCATTCCACCTCTCCTAAAACC 
ApxC A19E F GGTGGCATGGTTATGGGAAAGTTCTCCTTTACATC 
ApxC A19E R GATGTAAAGGAGAACTTTCCCATAACCATGCCACC 
ApxC S21A F GCATGGTTATGGGCAAGTGCTCCTTTACATCGAAAG 
ApxC S21A R CTTTCGATGTAAAGGAGCACTTGCCCATAACCATGC 
ApxC H24A F GTTATGGGCAAGTTCTCCTTTAGCTCGAAAGTGGCCG 
ApxIX H24A R CGGCCACTTTCGAGCTAAAGGAGAACTTGCCCATAAC 
ApxC N35A F GTGGCCGCTTTCTTTGTTAGCAATTGCTGTGCTACCTGCG 
ApxC N35A R CGCAGGTAGCACAGCAATTGCTAACAAAGAAAGCGGCCAC 
ApxC C58A F CGTGACGGTTTTCCTATTGCATTTGCTAGCTGGGCAAATTTG 
ApxC C58A R CAAATTTGCCCAGCTAGCAAATGCAATAGGAAAACCGTCACG 
ApxC D93A F CGTCGATGGTTTATAGCTTGGATAGCACCGTTCG 
ApxC D93A R CGAACGGTGCTATCCAAGCTATAAACCATCGACG 
ApxC R121A F CTGTTTAGGGCTATTGCAGTTGATCCGGACTCTC 
ApxC R121A R GAGAGTCCGGATCAACTGCAATAGCCCTAAACAG 
ApxC 161 R GCGCGAGCTCCCATTTTTTAGCTCACTCATTAATTCAAAG 
HlyA 679 F GCGCAAGCTTGATGGAAGTTGTGAAGGAGCAGGAGGTTTC 
HlyA 736 R GCGCGAGCTCCCATCAGTAAATTTACTGCCAAAAAACTTG 
ACP F GCGCAAGCTTGATGAGCACTATCGAAGAACGCGTTAAG 
ACP R GCGCGAGCTCCCCGCCTGGTGGCCGTTGATGTAATC 
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Supplemental Figure 1: ApxC substitutes for HlyC in activating the E.coli hemolysin protoxin. 
E.coli DH5α (TolC positive) transformed with plasmids encoding the hemolysin protoxin (LG583-HlyA), 
export proteins (LG575-HlyBD) and either pQE80 empty (control left), or encoding a TAAT (HlyC centre; 
ApxC right) and grown on blood agar plates. In the absence of a TAAT, colonies (arrowed) are non-
hemolytic, but expression of either E.coli HlyC or ApxC restores the hemolytic phenotype. Erythrocyte lysis 
assays confirmed HlyC and ApxC TAAT activities are comparable (100±5 % and 99±6 % activity 
respectively).  
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Supplemental Figure 2: Gel filtration of natively-purified recombinant ApxC. (a) The A280 trace is 
shown in blue and the elution peak marked in red, with SDS PAGE of fractions immediately below.  Dotted 
lines denote the elution maxima of protein standards bovine serum albumin 66kDa, carbonic anhydrase 
29kDa, and cytochrome c 12kDa. (b) Standard linear calibration plot of Ve/Vo (elution volume (mL) divided 
by void volume of the column (mL)) verses the base-10 logarithm of the molecular weight (kDa) for the three 
protein standards (white squares). A linear fit to the protein standards is shown as a solid black line 
(R²=0.99).  The point at which the measured Ve/Vo value for ApxC intersects the calibration curve is denoted 
by a black square with the measured elution point and corresponding log-molecular weight for ApxC shown 
as red dashed lines. From the calibration curve, ApxC elutes at an apparent molecular weight of 42 kDa 
consistent with a dimer of two 21 kDa monomers.  
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Supplemental Figure 3: Superposition of a pair of near-identical dimers related by 2-fold 
non-crystallographic symmetry. (a) Superposition of a pair of dimers derived from the asymmetric unit; the 
first composed of monomers A and C, the second of monomers B and D. The root mean square deviation 
(rmsd) for all Cα positions is 0.90 Å indicating the two arrangements are essentially identical. (b) 
Superposition of all 4 monomers.  Rmsd indicated is the mean value for all possible pairwise superpositions 
of monomers.  Deviations in structure are largely limited to the extreme N- and C-termini. 
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Supplemental Figure 4: Western blot of ApxC-CyaA T25 domain fusions. ApxC-CyaA T25 domain 
fusions used in the two-hybrid assays (Fig. 4d) were expressed in E.coli MC1061, and monitored by 
immunoblot using rabbit anti-CyaA primary (Santa Cruz Biotech) and donkey anti-rabbit dye-conjugated  
secondary (Licor) antibodies.  
Greene et al  : Page 36 of 37 
 
Supplemental Figure 5: The conserved TAAT cysteine is located in the protein core and is not 
required for TAAT activity. (a) Close-up of the conserved cysteine. (b) Context of Cys58 within the ApxC 
monomer. Cys58 is located within the hydrophobic core of the protein on the second β-strand. The side 
chain thiol (yellow) is located on the opposite side of the central sheet to residues that belong to the active 
site (green). Hydrophobic residues (purple) pack around the cysteine, sealing-in the side chain and 
preventing access to potential substrates. The location of the conserved cysteine precludes the possibility of 
a catalytic role for this residue. (c) TAAT activity of wild type (WT) and Cys58Ala ApxC (Western blot shows 
expression) assayed by in vivo activation of HlyA protoxin, read by erythrocyte lysis. Values above the bars 
indicate percentage of wild type activity ±SD.  
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Supplemental Figure 6: Potential mechanisms for toxin activation by TAATs. (a) The direct attack 
mechanism. (b) The covalent catalysis mechanism. Enzymatic residues are black, the target toxin lysine is 
green and acyl-ACP blue. The acyl chain is denoted 'R'. Curly arrows (red) denote electron pair movements. 
Possible roles for essential residues Asp93 and His24 are shown in context of each mechanistic scheme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
